Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
Sep 2020 |
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
Parsing the Paradox of Myelodysplastic Syndromes |
Dec 2020 |
Journal of clinical oncology: official journal of the American Society Clinical Oncologysd |
Myelodysplastic Syndromes (MDS) |
Paroxysmal nocturnal hemoglobinuria: Where we stand |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: Where are we going |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
Mar 2024 |
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations |
Dec 2023 |
Journal of Blood Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |